DURECT Corporation is a biopharmaceutical company focused on researching and developing innovative medicines aimed at treating pain and chronic diseases. The company offers a product line that includes ALZET osmotic pumps for experimental research and LACTEL biodegradable polymers for pharmaceutical and medical device applications. DURECT's pipeline features investigational drug candidates such as DUR-928, which is in Phase I and II development for regulating lipid homeostasis and inflammation, and POSIMIR, an investigational analgesic designed to deliver bupivacaine for extended post-surgical pain relief. The company employs proprietary oral, transdermal, and injectable delivery technologies that enhance the efficacy and safety of both small-molecule and biologic drugs. DURECT markets its products in the United States and internationally through distributors in Europe and Japan. Established in 1998 and headquartered in Cupertino, California, DURECT has formed strategic collaborations with several organizations to advance its pharmaceutical programs.
Southern Biosystems is develops, manufactures and sells biodegradable polymer and non-polymer drug delivery systems.
IntraEAR, Inc.
Acquisition in 1999
IntraEAR, Inc. was established in 1994 to develop and provide innovative, cost-effective ear related medical devices to the international otology and otolaryngology communities. In 1997, IntraEAR received FDA Approval for and launched the Round Window (Cath(, an accurate and controllable drug delivery catheter that targets the round window niche of the ear to treat inner ear disorders.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.